Structure | Chemical Name | CAS | MF |
|
CA 0.45 250MM DOE FLAT GSKT
|
|
|
|
CA 0.20 250MM DOE FLAT GSKT
|
|
|
|
CA 0.45 500MM DOE FLAT GSKT
|
|
|
|
CA 0.20 500MM DOE FLAT GSKT
|
|
|
|
CA 0.45 250MM DOE FLAT GSKT EPR
|
|
|
|
CBDcex*TAG ANTIBODY
|
|
|
|
Cancer Associated Antigen, Ovarian Tumor, Cell Culture Deriv
|
|
|
|
CA 0.45 250MM 2-222EPR/FLAT
|
|
|
|
Camlofyn HCL
|
|
|
|
CBDcenA*TAG ANTIBODY
|
|
|
|
cancerocerebral antigen
|
|
|
|
cancer basic protein
|
|
|
|
CANCERRISKASSESSMENT
|
|
|
|
cancer procoagulant
|
|
|
|
Cancell
|
|
|
|
CANCEREPIDEMIOLOGY:GENERAL
|
|
|
|
CANCERMECHANISMS
|
|
|
|
CANCER
|
|
|
|
CANCEREPIDEMIOLOGY:INDUSTRIAL
|
|
|
|
CANCEREPIDEMIOLOGY:LIFESTYLE
|
|
|
|
CANCEREPIDEMIOLOGY
|
|
|
|
CANCER ASSOCIATED, TPA
|
|
|
|
CANCER ANTIGEN (CA 27-29)
|
|
|
|
CANCER ANTIGEN (CA-50)
|
|
|
|
CancerSirnaMetastasisSubset
|
|
|
|
CancerAntigenCa125(OvarianCancer)CalibratorGrade
|
|
|
|
CancerAntigenCa19-9(GastrointestinalCancer)AntigenGrade
|
|
|
|
CancerAntigenCa125(OvarianCancer)AntigenGrade
|
|
|
|
CancerAntigenCa15-3(BreastCancer)
|
|
|
|
CancerAntigenCa72-4AntigenGrade
|
|
|
|
CancerAntigenCa19-9(GastrointestinalCancer)
|
|
|
|
CancerAntigenCa15-3(BreastCancer)AntigenGrade
|
|
|
|
CancerSirnaDNARepairSubset
|
|
|
|
Cancer Associated Antigen, Breast Tumor, Human Fluids
|
|
|
|
CancerAntigenCa19-9(GastrointestinalCancer)CalibratorGrade
|
|
|
|
Cancentrine
|
29477-90-5
|
|
|
CancerAntigenCa125(OvarianCancer)GroupA
|
|
|
|
CancerAntigenCa15-3(BreastCancer)CalibratorGrade
|
|
|
|
CancerAntigenCa125(OvarianCancer)CalibratorGrade(LowCrossReactivity)
|
|
|
|
CancerAntigenCa50CalibratorGrade
|
|
|
|
CancerSirnaApoptosisSubset
|
|
|
|
CancerSirnaCellCycleSubset
|
|
|
|
Cancer Vaccines
|
|
|
|
cancer-associated retinopathy antigen
|
135844-11-0
|
|
|
cancer suppressive factor
|
|
|
|
cancer-recognition, immunedefense suppression, serine protease protection peptide
|
|
|
|
CancerAntigenCa15-3(BreastCancer)CalibratorGrade(LowCrossReactivity)
|
|
|
|
CancerAntigenCa125(OvarianCancer)GroupB
|
|
|
|
CancerSirnaGrowthFactorSubset
|
|
|
|
CancerAntigenCa125(OvarianCancer)
|
|
|
|
CancerSirnaAngiogenesisSubset
|
|
|
|
CancerSirnaTumorSuppressorSubset
|
|
|
|
CancerBulkMaterials
|
|
|
|
CBDcenA*TAG PRIMER
|
|
|
|
Cancer Associated Antigen, TAG-72, Human Fluids
|
|
|
|
CA 0.45 500MM 2-222FPM/FLAT CLOSED
|
|
|
|
CA 0.45 250MM 2-222FPM/FLAT CLOSED
|
|
|
|
CA 0.45 500MM 2-222/FLAT CLOSED
|
|
|
|
CANDALUM (RHODIA)
|
|
|
|
CBDclos*TAG PRIMER
|
|
|
|
CBDclos*TAG ANTIBODY
|
|
|
|
C8-18 and C18-Unsaturated alkyldicarboxylic acid, triethanolamine salt
|
68603-85-0
|
|
|
Candesartan
|
139481-59-7
|
C24H20N6O3
|
|
CANDELILLA(EUPHORBIACERIFERA)WAX
|
|
|
|
CANDESARLAN
|
|
|
|
CANDESARTAMCILEXETIL
|
|
|
|
CANDELILLIA WAX
|
|
|
|
Candesartan cilexetil
|
145040-37-5
|
C33H34N6O6
|
|
CANDELILLA WAX
|
8006-44-8
|
|
|
CANDESARTAN CILEXETIL-D11
|
1261393-19-4
|
C33H23D11N6O6
|
|
CANDESARTAN-D4
|
1346604-70-3
|
C24H16D4N6O3
|
|
CANDELARIELLAREFLEXA
|
|
|
|
Candesartan Cilextile
|
|
|
|
CandesartanCilexetil/TritylCandesartanCilexetil
|
|
|
|
CandesartanCilexetill,Amias&Atacand
|
|
|
|
CandesartanCilexetill
|
|
|
|
CandesartanCilexetil,Hypotensive
|
|
|
|
CandesartanMethyl-2-(Tert-ButoxyCarbonylAmino)-3-NitroBenzoate
|
|
|
|
Candesartan/TritylCandesartan
|
|
|
|
Candesartan cilextil
|
|
|
|
candelalide C
|
|
|
|
candelalide A
|
|
|
|
candelalide B
|
|
|
|
Candersartan
|
|
|
|
CANDELILLA WAX HYDROCARBONS
|
|
|
|
CANDESARTAN B
|
|
|
|
CANDESARTANCILEXETIL
|
|
|
|
CANDELILLA
|
|
|
|
CANDERSARTAN CILEXETIL [3H(G)]
|
|
C33N6O6T34
|
|
Candidoside A
|
|
C41H66O13
|
|
CANDIDAOLEOPHILAISOLATE
|
|
|
|
CANDIDULIN
|
1403-24-3
|
|
|
CANDIDA
|
|
|
|
CANDIDSPP
|
|
|
|
CANDIDASPP
|
|
|
|
candidalactone
|
|
|
|
candidusin C
|
|
|
|
Candida growth regulation protein 1
|
|
|
|
candiplanecin
|
79620-36-3
|
|
|
canditoxin
|
12626-37-8
|
|